

## **CLAIMS**

1. Use of an antibody in the manufacture of a medicament for the treatment of a cancer or a tumor or an infectious disease; wherein the antibody is a humanized antibody capable of binding to human Tim-3, comprising:  
  
a heavy chain variable region (VH) comprising a VH-CDR1 amino acid sequence of SEQ ID NO 3, a VH-CDR2 amino acid sequence of SEQ ID NO 26 and a VH-CDR3 amino acid sequence of SEQ ID NO 5; and a light chain variable region (VL) comprising a VL-CDR1 amino acid sequence of SEQ ID NO 6, a VL-CDR2 amino acid sequence of SEQ ID NO 7 and a VL-CDR3 amino acid sequence of SEQ ID NO 27.
2. Use of an antibody in the manufacture of a medicament for the treatment of a cancer or a tumor or an infectious disease; wherein the antibody is a humanized antibody capable of binding to human Tim-3, comprising:  
  
a heavy chain variable region (VH) comprising a VH-CDR1 amino acid sequence of SEQ ID NO 3, a VH-CDR2 amino acid sequence of SEQ ID NO 4 and a VH-CDR3 amino acid sequence of SEQ ID NO 5; and a light chain variable region (VL) comprising a VL-CDR1 amino acid sequence of SEQ ID NO 6, a VL-CDR2 amino acid sequence of SEQ ID NO 7 and a VL-CDR3 amino acid sequence of SEQ ID NO 8.
3. The use according to claim 1, wherein the antibody comprises:
  - (a) a heavy chain variable domain comprising at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO 28, and a light chain variable domain having at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO 36; or
  - (b) a heavy chain variable domain comprising at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO 28, and a light chain variable domain having at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO 30.
4. The use according of claim 1 or claim 3, wherein the antibody comprises:
  - (a) a heavy chain variable domain comprising one or more conservative substitutions of SEQ ID NO 28, and a light chain variable domain comprising one or more conservative substitutions of SEQ ID NO 36; or

- (b) a heavy chain variable domain comprising one or more conservative substitutions of SEQ ID NO 28, and a light chain variable domain comprising one or more conservative substitutions of SEQ ID NO 30.
5. The use according to claim 1, wherein the antibody comprises:
- (a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO 28, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO 36; or
- (b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO 28, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO 30.
6. The use according to any one of claims 1 to 5, wherein the antibody is a Fab, F(ab')<sub>2</sub>, Fv, or a single chain Fv (ScFv).
7. The use according to any one of claims 1 to 6, wherein the antibody comprises a heavy chain constant region of the subclass of IgG1, IgG2, IgG3, or IgG4 or a variant thereof, and a light chain constant region of the type of kappa or lambda or a variant thereof.
8. The use according to claim 7, wherein the antibody comprises a variant heavy chain constant region of the subclass of IgG1, IgG2, IgG3, or IgG4, wherein the variant heavy chain constant region provides a reduced or eliminated effector function.
9. The use according to claim 8, wherein the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).
10. The use according to claim 7, wherein the antibody comprises a heavy chain constant region of human IgG1 or a variant thereof.
11. The use according to claim 10, wherein the variant heavy chain constant region of human IgG1 comprises one or more mutations selected from a group consisting of E<sub>233</sub>P, L<sub>234</sub>A, L<sub>235</sub>A, L<sub>236</sub>Δ and P<sub>329</sub>A.
12. The use according to claim 11, wherein the antibody comprises a variant human IgG1 heavy chain constant region comprising the amino sequence of SEQ ID NO 21, and a human IgG1 kappa light chain constant region.
13. The use according to any one of claims 1 to 12, wherein the cancer is selected from a lung cancer, a liver cancer, a stomach cancer, a cervical cancer, a melanoma, a renal cancer, a breast cancer, a colorectal cancer, a leukemia, a lymphoma, an ovarian cancer, a head and neck cancer or a metastatic lesion of the cancer.

14. The use according to any one of claims 1 to 13, wherein the infectious disease is a chronic viral infection, selected from HIV infection and HCV infection.
15. A humanized antibody capable of binding to human Tim-3, comprising:  
a heavy chain variable region (VH) comprising a VH-CDR1 amino acid sequence of SEQ ID NO 3, a VH-CDR2 amino acid sequence of SEQ ID NO 4 and a VH-CDR3 amino acid sequence of SEQ ID NO 5; and a light chain variable region (VL) comprising a VL-CDR1 amino acid sequence of SEQ ID NO 6, a VL-CDR2 amino acid sequence of SEQ ID NO 7 and a VL-CDR3 amino acid sequence of SEQ ID NO 8.